Zobrazeno 1 - 10
of 222
pro vyhledávání: ''
Autor:
Takashi Kojima, Satoshi Fujii, Hiroyuki Daiko, Hisanaga Nomura, Tomonori Yano, Toshikatsu Kawasaki, Ken Demachi, Nobuo Mochizuki, Daiki Tsuji, Haruki Matsuzawa, Kunihiko Itoh
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:315-324
The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is a newly developed chemotherapy regimen for esophageal cancer. Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chem
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:113-119
To determine the maximum tolerated dose (MTD) and recommended dose (RD) of modified FLOT regimen (fluorouracil plus leucovorin, oxaliplatin and docetaxel) for treating Chinese patients with metastatic adenocarcinoma of stomach. Chinese patients with
Autor:
Yukana Tomoda, Yuya Hirasawa, Takuya Tsunoda, Ayako Tsuboya, Ken-ichi Fujita, Hiroo Ishida, Yusuke Kondo, Yasutsuna Sasaki, Ryotaro Ohkuma, Natsumi Matsumoto, Hiroyuki Kusuhara, Yutaro Kubota, Hirotsugu Ariizumi, Tomoyuki Ishiguro
Publikováno v:
Cancer chemotherapy and pharmacology. 88(3)
SN-38, a pharmacologically active metabolite of irinotecan, is taken up into hepatocytes by organic anion transporting polypeptide (OATP) 1B1. The effects of functional OATP1B1 521T>C on the pharmacokinetics of SN-38 remain controversial. Here, we pr
Autor:
Yasuhiro Kato, Kageaki Watanabe, Shoko Kawai, Makiko Yomota, Yukio Hosomi, Tatsuru Okamura, Yusuke Okuma
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background Few studies have investigated the clinical efficacy of third- and later-line of chemotherapy after standard chemotherapy for previously treated advanced non-small cell lung cancer (NSCLC). We prospectively evaluated the efficacy and safety
Autor:
Keigo Hara, Makoto Sakai, Ken Shirabe, Hideyuki Saito, Tomonori Yoshida, Shin-ei Noda, Makoto Sohda, Takashi Nakano, Yuji Kumakura, Tatsuya Miyazaki, Kengo Kuriyama, Kazutoshi Murata, Takehiko Yokobori, Hiroyuki Kuwano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:1121-1126
To evaluate the efficacy of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for cervical esophageal cancer (CEC), we performed a retrospective analysis of CEC patients treated by DCF-RT at a single institution. We c
Autor:
Sayaka Arisaka, Toshiaki Kadokura, Itaru Endo, Ryusei Matsuyama, Koki Goto, Takafumi Kumamoto, Ryutaro Mori, Masataka Taguri, Yusuke Suwa, Mari Sato
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To assess the predictive ability of the maximum chemiluminescence intensity (CImax) for severe neutropenia (SN) during neoadjuvant chemo(radio)therapy [NAC(RT)] in patients with advanced pancreatic or biliary tract cancer. Methods Clinicopath
Autor:
Mustafa Karaagac, Ali Murat Tatli, Mustafa Ozdogan, Ali Ayberk Besen, Ahmet Bilici, Sema Sezgin Goksu, Mustafa Atcı, Muhammet Ali Kaplan, Senar Ebinç, Mukremin Uysal, Sabin Göktaş Aydın, Hasan Şenol Coşkun, Mehmet Artac, Caglayan Geredeli, Huseyin Mertsoylu
Publikováno v:
Cancer chemotherapy and pharmacology. 88(5)
Purpose In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy. Methods Patients who were treated with platinum-based chemotherapy an
Autor:
José Federico González González, Jaime Feliu, P. Vicente, Esther Casado Gonzalez, Guillermo Lopez-Vivanco, Ana Montes, Carmen Garcia Piernavieja, Teresa Macarulla, Irene Gonzalez Cebrian, A. Muñoz, Manuel Valladares-Ayerbes, Mónica Jorge Fernández, Juan Ignacio Delgado-Mingorance, Bartomeu Massuti, Ana Albero, Rebeca Mondéjar Solís, Guillermo Quintero-Aldana
Publikováno v:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Digital.CSIC. Repositorio Institucional del CSIC
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Digital.CSIC. Repositorio Institucional del CSIC
[Purpose] To evaluate the health-related quality of life (HRQoL), global health status (GHS), and deterioration-free survival of an elderly population (> 70 years) with unresectable locally advanced (LAPC) or metastatic pancreatic cancer (mPC) treate
Autor:
Norio Ureshino, Takefumi Yoshida, Takayuki Shimose, Tetsuo Tohyama, Hideo Baba, Masahito Kotaka, Tatsuya Kinjo, Hirofumi Kawanaka, Shinichiro Mori, Seiichiro Kai, Hiroshi Saeki, Masaki Mori, Hironori Samura, Koji Ando, Kippei Ohgaki, Yoshihiko Maehara, Kazuma Kobayashi, Akitaka Makiyama, Hiroshi Okumura, Eiji Oki
Publikováno v:
Cancer chemotherapy and pharmacology. 86(2)
This study was designed to assess the tolerability, efficacy, and safety of tri-weekly irinotecan plus S-1 (IRIS) and weekly cetuximab in patients with metastatic colorectal cancer (mCRC). The main eligibility criteria were RAS wild-type mCRC with no
Autor:
Yukio Yoshida, Kazuhiko Shioji, Kazuhiro Uesugi, Kumiko Umemoto, Takeshi Terashima, Chigusa Morizane, Masayo Motoya, Hideaki Takahashi, Tetsuo Akimoto, Makoto Ueno, Masafumi Ikeda, Ikuhiro Yamada, Satoshi Shimizu, Junji Furuse, Nobumasa Mizuno, Yasushi Kojima
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background UGT1A1 *28 and *6 polymorphism is associated with reduced enzyme activity and severe toxicities of irinotecan, especially in patients with homozygous or heterozygous for UGT1A1*28 or *6 polymorphism for both UGT1A1*28 and *6 (double-varian